Which medications in the drug class FGFR Inhibitors are used in the treatment of Renal Transitional Cell Carcinoma?

Updated: Nov 05, 2019
  • Author: Bagi RP Jana, MD, MBA, MHA, FACP; Chief Editor: E Jason Abel, MD  more...
  • Print

FGFR Inhibitors

Fibroblast growth factor receptor (FGFR) inhibitor; FGFRs are a family of receptor tyrosine kinases. Inhibition of FGFR phosphorylation and signaling decreases cell viability in cell lines expressing FGFR genetic alterations, including point mutations, amplifications, and fusions.


Indicated for locally advanced or metastatic urothelial carcinoma that has fibroblast growth factor receptor-2 (FGFR2) or FGFR3 genetic alterations and progressed during or following at least 1 line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!